Skip to content

Impact of traditional ayurvedic drug Lipidom and Yoga Intervention vs Placebo in Dyslipidemia.

To Assess the Efficacy of Ayurvedic Drug formulation Lipidom Vs Yoga Intervention Vs Placebo in Patients with Dyslipidemia: An Open Label Three Arm Randomized Control Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/046979
Enrollment
114
Registered
2022-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases Health Condition 2: E785- Hyperlipidemia, unspecified

Interventions

None listed

Sponsors

Patanjali Research Institute governed by Patanjali Research Foundation Trust
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult male and non-pregnant female population pre-diagnosed dyslipidemia. 2. Subject should have followed the level of TC, TG, LDL, HDL according to NCEP ATP III guideline. 3. BMI 20-30 kg/m2. 4. Subject willingness to participate and sign the informed consent form and ready to comply with protocol measures. 5. Subjects who can do yoga intervention.

Exclusion criteria

Exclusion criteria: 1. Medical history of unstable angina. 2. Myocardial infarction. 3. I patients is having active cardiac, hepatic, renal disease or have history of stroke within past three months. If patients having active malignant condition. 4. Pregnant/Lactation

Design outcomes

Primary

MeasureTime frame
Change in laboratory parameters of lipid profile compared to baseline after 8 weeks of Ayurvedic intervention. Change in laboratory parameter of lipid profile compared to baseline after 3 months of yogic practices. Change in laboratory parameter of lipid profile compared to baseline after 3 months of placebo.Timepoint: Baseline, week 4 and week 8.

Secondary

MeasureTime frame
Changes in the level of quality of life by HRQoL 36, depression, anxiety, stress levels by DASS, lifestyle modification by SLIQ, and fatigue by MFI questionnaire. Treatment satisfaction and adherence.Timepoint: Baseline, week 4 and week 8.

Countries

India

Contacts

Public ContactPriyanka Rani

Patanjali Yog Gram

principal.investigator@prft.in7302254793

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026